Document Type

Article Presentation

Original Publication Date


Date of Submission

January 2021


This presentation gives a brief overview of the study conducted by Fantini, J., Chahinian, H., & Yahi, N. on nSynergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal. The study considered two drugs, hydroxychloroquine (CLQ) and azithromyocin (ATM), as potential treatments for curing COVID. Hydroxychloriquine is a drug commonly used in the treatment of malaria but has been shown by recent studies to not be an effective cure against COVID on its own. Azithromyocin is a commonly used antiobiotic that was also considered in this study. Hydroxychloriquine interacts with the ganglioside-binding domain of the SARS-CoV-2 protein and targets the virus, while azithromyocin saturates the virus attachment sites and targets the attachment site of the virus. The study used molecular dynamics, a method visualizing interactions digitally on a molecular level, to show that the use of CLQ in conjunction with ATM showed promising results in preventing contact of the virus with host cells. Clinical trials on human subjects are being performed by the NIH and are currently in Phase 2.


© The Author(s)